Cell Microsystems
Durham, US · Founded 2021 · Delaware corporation · 2 known investors
Cell Microsystems develops automated instruments for cellular and molecular workflows used in life science research, including oncology, stem cell biology, and regenerative medicine. Its products support scientists in laboratory research and single-cell isolation and analysis.
Founders & leadership
NA
Nancy AllbrittonNamed on SEC filing
YW
Yuli WangNamed on SEC filing
MM
Matthew MegaroNamed on SEC filing
GP
Gary PaceNamed on SEC filing
CS
Christopher SimsNamed on SEC filing
SM
Scott McGinnisPresident
JH
Jessica HartmanSenior Director of Product Applications
Investors · 2
Reported raises · per SEC filings
Form D private placements$21M disclosed across 3 rounds · 2019–2023
▶$6.5MraisedAug 2023 · 1 investors · BiotechnologyRule 506(b)
▶$6.5MraisedAug 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rob CaponeDirector
- Gary M. PaceExecutive Officer, Director
- Christopher SimsExecutive Officer, Director
- Alexander HerzickDirector
- Deval LashkariDirector
- Brett WilliamsDirector
- Offering amount
- $13M
- Amount sold
- $6.5M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$12.7MraisedNov 2021 · 17 investors · BiotechnologyRule 506(b)
▶$12.7MraisedNov 2021 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rob CaponeDirector
- Christopher SimsExecutive Officer, Director
- Gary M. PaceExecutive Officer, Director
- Alexander HerzickDirector
- Deval LashkariDirector
- Offering amount
- $12.7M
- Amount sold
- $12.7M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.9MraisedJun 2019 · 12 investors · BiotechnologyRule 506(b)
▶$1.9MraisedJun 2019 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nancy AllbrittonDirector
- Yuli WangDirector
- Matthew MegaroDirector
- Gary PaceExecutive Officer, Director
- Christopher SimsExecutive Officer, Director
- Offering amount
- $2.2M
- Amount sold
- $1.9M
- First sale
- Jun 2019
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapMolecular Devices160 shared keywordsMolecular Devices develops laboratory instruments and automated workflows for life science research, including SpectraMax microplate readers, high-content screening and imaging systems, colony-picking devices, and 3D organoid and cell culture solutions. It serves researchers in drug discovery, cell line development, and screening, supported by AI-enabled analysis software and GxP compliance tools.
Danaher130 shared keywordsDanaher is a diversified conglomerate that operates a portfolio of businesses in life sciences, diagnostics, and related fields, guided by its Danaher Business System (DBS) operating model.
Companies competing with Cell Microsystems for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 19 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $838.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $292K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $256.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $1.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $300.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $297.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2019 | $267.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $283.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2017 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2017 | $250.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2016 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2016 | $224.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $189.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $151.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Cell Microsystems do?
- Cell Microsystems develops automated instruments for cellular and molecular workflows used in life science research, including oncology, stem cell biology, and regenerative medicine. Its products support scientists in laboratory research and single-cell isolation and analysis.
- Who are Cell Microsystems's investors?
- Cell Microsystems's investors include Telegraph Hill Partners, IDEA NC.
- How much funding has Cell Microsystems raised?
- Cell Microsystems has disclosed $21M raised across 3 rounds.
- Where is Cell Microsystems headquartered?
- Cell Microsystems is headquartered in Durham, US.